Second Massachusetts Company Takes Precautions in Meningitis Outbreak Linked to Pharmaceuticals
By: KARK 4 News
Updated: November 1, 2012
As a consequence of the recent multi-state outbreak of fungal meningitis associated with products manufactured by New England Compounding Center (NECC) in Massachusetts, the US Food and Drug Administration (FDA) has expanded its investigation to include other affiliated pharmaceutical compounding companies.
Based on findings from this FDA investigation, Ameridose, LLC in Westborough, Massachusetts, is conducting a voluntary recall of any unexpired products.
The Arkansas Department of Health (ADH) is working with the FDA and the Centers for Disease Control and Prevention (CDC) to identify Ameridose products that may have been sent to Arkansas facilities in order to assure that the products are removed from the shelves.
The ADH will be contacting affected facilities and encouraging them to take appropriate action.
According to Nate Smith, MD, ADH deputy director and state epidemiologist, "To date, there are no reported human illnesses associated with Ameridose products."
The ADH will issue further advisories as deemed necessary.
Based on findings from this FDA investigation, Ameridose, LLC in Westborough, Massachusetts, is conducting a voluntary recall of any unexpired products.
The Arkansas Department of Health (ADH) is working with the FDA and the Centers for Disease Control and Prevention (CDC) to identify Ameridose products that may have been sent to Arkansas facilities in order to assure that the products are removed from the shelves.
The ADH will be contacting affected facilities and encouraging them to take appropriate action.
According to Nate Smith, MD, ADH deputy director and state epidemiologist, "To date, there are no reported human illnesses associated with Ameridose products."
The ADH will issue further advisories as deemed necessary.
